Entest BioMedical Inc. (ENTB)

Entest BioMedical Inc. trades under the symbol ENTB and is the parent company of Zander Therapeutics Inc.  The focus of Zander Therapeutics, Inc. is to develop small molecule immunotherapies and cancer stem cell therapies for the veterinary market.  The company is specifically focused on animal therapies that address unmet medical needs. Zander is looking to increase the quality of life in animals through therapies involving small molecules, stem cell treatments and the body’s own immune system. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.

Zander is wholly owned by Entest BioMedical Inc. (a publicly traded company — OTCPINK: ENTB). Zander is focused on developing veterinary treatments for cancer and autoimmune disorders (such as arthritis). We are targeting canine cancer, especially considering that 50% of all dogs over the age of 10 years will develop some form of cancer. Feline Leukemia (FL) is another focal point, with 2-3% of all cats in the United States carrying the feline leukemia virus. Additionally, we are looking at arthritis in animals from dogs and cats to thoroughbred horses.

Our goal is to utilize small molecule therapies for treating autoimmune disorders (arthritis) in animal companions, feline leukemia (cats) and canine cancer (dogs). Currently, Zander Therapeutics is developing products treating blood disorders using small molecules based on nuclear receptor NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP).

Ongoing objectives include gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cells through Zander’s patented molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy-treated cancer patients.

Areas of interest to Zander Therapeutics include:

  • Autoimmune disorders (arthritis)
  • Feline Leukemia
  • Exercise Induced Pulmonary Hemorrhage
  • Gene Silencing immunotherapy for cancer treatment
  • Small molecule treatments for cancer
  • Treatment for bone marrow suppression in animals receiving chemotherapy and radiation

Company Website:

www.zandertherapeutics.com

Contact Info:

Zander Therapeutics, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942
U.S.A.

​info@zandertherapeutics.com
Telephone: (619) 702-1404
Fax: (619) 330-2328


Company News:

Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders

Dividend is Approximately 83% Payout of Zander's Issued and Outstanding Common Shares SAN DIEGO , September 29, 2017 /PRNewswire/ -- Entest BioMedical, Inc. (OTC:ENTB) today announced that its Board of ...

Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board

SAN DIEGO , September 13, 2017 /PRNewswire/ -- Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) announced the appointment of Robin Beat Gasser , DVM, Ph.D. as a Senior ...

Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators

SAN DIEGO , July 26, 2017 /PRNewswire/ -- Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) reported that researchers for Regen BioPharma Inc. have identified what the company ...

Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board

Brian Devine, retired Chairman of PETCO, a leading pet specialty retailer, has agreed to serve as Chairman of the Business Advisory Board for Zander Therapeutics, Inc., a veterinary life sciences company and subsidiary of Entest BioMedical Inc. (ENTB). "Mr. Devine's vast expertise in the animal health market, as well as his legacy of support for pet health, are an ideal match for our company," says David Koos, PhD, Chairman and CEO of Zander.

Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies

SAN DIEGO, June 13, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (OTC-PINK: ENTB) subsidiary, Zander Therapeutics, Inc. has tested compounds that act on human cells in suppressing the immune system in ...

Key Personnel:


David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 31 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.